Clinical Scorecard: Does Kaposi’s sarcoma signal the conclusion of the OX40/OX40L pathway in atopic dermatitis treatment?

At a Glance

Key Highlights

• Recent cases of Kaposi’s sarcoma linked to OX40/OX40L therapies raise safety concerns and necessitate a reevaluation of treatment protocols.
• Rocatinlimab and amlitelimab showed initial clinical activity in atopic dermatitis, but ongoing safety monitoring is critical.
• Kaposi’s sarcoma cases have shifted the focus from efficacy to risk management in therapy development, highlighting the need for careful patient selection.
• The biological rationale for OX40/OX40L in atopic dermatitis remains strong despite safety concerns, warranting further investigation.
• Future development must balance therapeutic benefits with immune surveillance risks, emphasizing the importance of risk mitigation strategies.

Guideline-Based Recommendations

Diagnosis

Management

• Consider existing therapies like dupilumab and JAK inhibitors before OX40/OX40L targeting, especially in patients with a history of malignancies.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

New biologics must demonstrate clear advantages over existing treatments in terms of efficacy, safety, and patient selection criteria.

Clinical Best Practices

• Incorporate risk assessment for malignancies in treatment planning, including patient education on potential risks.
• Ensure informed consent includes discussion of potential risks associated with OX40/OX40L therapies, particularly regarding malignancies.
• Stay updated on emerging data regarding safety and efficacy of OX40/OX40L targeting, and provide ongoing education for healthcare providers.

Related Resources & Content

• Clinical data on OX40/OX40L in atopic dermatitis
• Kaposi’s sarcoma and OX40/OX40L therapies